Sentence examples for benign and malignant mesothelial from inspiring English sources
Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells.
Noteworthy, RAGE-1 was expressed in all benign and malignant mesothelial cells investigated, with the exception of MES-CM98 and MES-2 MM cells (Table 1).
The distribution of RAGE-1 in benign and malignant mesothelial cells closely resembles that of melanocyte differentiation antigens in melanoma (Traversari, 1999), and suggests for a possible tissue-specificity of RAGE-1 expression.
The patterns of gelatinolytic activity seen in MM, IP and UP are likely to reflect both the nature and extent of the inflammatory cell infiltrate in these conditions, and between benign and malignant mesothelial cells.
26 Although IHC/ICC is a powerful tool to identify cells of mesothelial origin and differentiate MPM from pleural metastases of other primary carcinomas, the ability of this technique to distinguish between benign and malignant mesothelial proliferations remains controversial.
Differentiation of MPM from benign disease can also be challenging, for example: well-differentiated epithelial mesothelioma vs. reactive mesothelial proliferation, sarcomatoid or desmoplastic mesothelioma vs. benign reactive pleural fibrosis, and benign vs. malignant mesothelial proliferation.
However, there is still no reliable marker separating benign from malignant mesothelial proliferations with sufficient sensitivity and specificity.
On the other hand, no information was provided in SEER on results of an immunohistochemical panel, which has been recommended to distinguish benign from malignant mesothelial proliferations [ 45].
Saad et al (2005) demonstrated that the choice of antibody clone could greatly influence the accuracy of the use of anti-MUC1/EMA antibodies in distinguishing benign from malignant mesothelial cells in a diagnostic setting.
8, 9 Diagnosis of MPM involves first determining the mesothelial origin of the lesion by morphology and IHC/ICC and then differentiating between benign and malignant conditions.
